Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

OBJECTIVES: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatmen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://ncbi.nlm.nih.gov/pubmed/32220908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-027665
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky